Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
about
Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancerLower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways.The global impact of endoscopic ultrasound (EUS) regarding the survival of a pancreatic adenocarcinoma in a tertiary hospital.Targeted drug delivery in pancreatic cancerATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modificationMUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progeniesInhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathwayMechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphateALCAM (CD166) expression and serum levels in pancreatic cancerTLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling.Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.Management of mucinous cystic neoplasms of the pancreas.Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growthAdjuvant and neoadjuvant treatment in pancreatic cancerPolyphenol-rich extract of Salvia chinensis exhibits anticancer activity in different cancer cell lines, and induces cell cycle arrest at the G₀/G₁-phase, apoptosis and loss of mitochondrial membrane potential in pancreatic cancer cells.The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerBlockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activityEmodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cellsMucinous Cystic Neoplasms of PancreasEpigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer.A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma.Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: adenosylcobalamin destruction and formation of a nucleotide-based radical.Effect of the Natural Product Triptolide on Pancreatic Cancer: A Systematic Review of Preclinical StudiesPreclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
P2860
Q24336620-E817B694-1490-4376-B5E2-3A4D37C78211Q30831967-FB50333A-5DB5-4ECB-8D3C-18427509D998Q33389172-0B337EB1-4813-41D2-926E-C49D70A6EE25Q33520811-3D39E611-41FC-4C22-BDA7-45DACC03B8A5Q33532201-FC506E12-5491-4C58-B34F-235ADF5BF85AQ33625651-5F182E67-8FBD-4D60-A4F4-91D87138B2E2Q33634888-81733042-0C2C-4EE6-AE06-01048E464882Q33791851-F409E28C-4049-4507-A5B4-157A9209D9D3Q33938044-D850E652-7BB4-44F0-BADC-D570BFFE972EQ33948775-BBA067DE-B6E5-42E4-BFB2-CD8BC7797A4EQ33957943-A52025C2-AF3D-4A9F-9B24-611EEA0EFA5AQ34048376-333DD332-BC2C-4C27-BD36-FBDDBCE4968CQ34321201-1B45771A-827A-446C-A268-0B2E6D30E790Q34344787-EB52BBA1-2978-4719-AAE3-DF93249B3507Q34382586-C61D2870-1738-4943-8CC2-07B700383EDBQ34385132-4D0C0595-A0B6-42D3-AB54-040B6820E753Q34812100-3CD0108C-B4C9-4A48-A7F5-77250F6C1062Q35886631-A7A1F3C7-49CF-4D10-802D-257CEFB37D9FQ36089689-0EE94888-091D-472D-85EE-80F847CD80C7Q36123027-765736E8-C0D3-495D-81CB-2001D9598272Q36351453-3525011B-AF3D-456F-B9C0-7D8772B46348Q36499644-B6FEFCA2-0470-474F-9ADB-4F9AAC85273AQ36645798-40DDFC3B-6261-4917-99D8-97B77E1E8975Q37071513-F0C673F6-B467-4B8A-9C91-3C29E45607D3Q37311556-40B3E38E-A9F8-4589-AC19-39DF02F43285Q37853945-16611B69-4423-4007-940A-D3AFC55DD312Q37994505-5FE21278-1A24-44DE-ADC6-6098698DFE97Q38184985-8DEC4773-E492-42F1-9A7D-30CF500C14F4Q38706044-7B581533-2C5D-425D-AF05-33CC11DF557CQ39024706-A5FDEA89-7930-4C3C-B1B4-E5AF9F21A614Q39294074-45560B22-82F5-4C57-AE08-DC76AF9B3BF1Q40465500-2DA7A8E3-677E-4BB2-85A1-19E366C58D3EQ41547393-2FD0112E-D858-4E41-8AB8-9B8AFFC26ED9Q41623726-2BFAD50A-E682-4FC1-AD2B-B17D6A0F249BQ43091585-A3396AF5-DEF4-4628-8485-9F2AED91CB3EQ47317142-169849D4-0B80-404D-9D6F-4FF649CF6C2FQ48193841-71141953-ADB6-4BA7-BCE5-D3422377CD65Q49215955-C89238F6-9A4D-414E-A26E-5598812B462EQ49491161-5E9B8627-603E-4555-AC0A-540CECE117EBQ50553669-5B46B490-6CB3-4A7D-AC77-5202C069B0EA
P2860
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of advanced pancreat ...... inations and targeted therapy.
@en
Treatment of advanced pancreat ...... inations and targeted therapy.
@nl
type
label
Treatment of advanced pancreat ...... inations and targeted therapy.
@en
Treatment of advanced pancreat ...... inations and targeted therapy.
@nl
prefLabel
Treatment of advanced pancreat ...... inations and targeted therapy.
@en
Treatment of advanced pancreat ...... inations and targeted therapy.
@nl
P2093
P1476
Treatment of advanced pancreat ...... binations and targeted therapy
@en
P2093
Fernando Rivera
Ma Eugenia Vega-Villegas
Matilde Salcedo
P304
P356
10.1016/J.CTRV.2008.11.007
P577
2009-01-07T00:00:00Z